[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Royal Brompton & Harefield NHS Foundation Trust\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":382},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,15,0,[8,44,61,86,118,138,162,188,214,240,269,295,316,340,362],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":24,"conditions":25,"keywords":28,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":43},"100634738","the-physiotherapy-assessment-of-breathing-pattern-disorder-100634738",false,"NCT07543588","The Physiotherapy Assessment of Breathing Pattern Disorder","An Evaluation of Physiotherapy Assessment; A Mixed Methods Study to Evaluate the Physiotherapy Assessment of Breathing Pattern Disorder","PHAB","Inclusion Criteria (Breathing Pattern Disorder group)\n\n* Adults aged above 18 years\n* Outpatient referrals for 'unexplained breathlessness' or possible breathing pattern disorder\n* Primary BPD (no other significant respiratory or cardiology diagnosis)\n* Secondary BPD (patients with a diagnosis of asthma)\n* Able to complete up to four sessions of outpatient physiotherapy intervention Exclusion Criteria\n* Patients with a respiratory diagnosis including COPD, ILD, Bronchiectasis and Cystic Fibrosis or structural heart disease\n* Pregnancy\n* Unable to give informed consent\n* Anyone currently participating in pulmonary\u002Fcardiac rehabilitation\n* Anyone receiving specialist ENT speech and language therapy for Upper airway symptoms",true,"ALL","18 Years",{"count":21,"type":22},150,"ESTIMATED","OBSERVATIONAL","This study aims to evaluate a clinical tool called the Breathing Pattern Assessment Tool (BPAT), which is used by physiotherapists to assess breathing pattern disorder (BPD). BPD is a condition where breathing is inefficient or out of sync with the body's needs, leading to symptoms such as breathlessness.\n\nThe study will investigate whether the BPAT is a reliable and accurate way to identify and assess BPD, and whether it can be used to monitor changes over time, particularly following physiotherapy treatment. It will also compare BPAT scores with other commonly used questionnaires that measure breathlessness and breathing symptoms.\n\nParticipants will include patients with BPD, patients with asthma, and healthy individuals. Patients with BPD will attend physiotherapy sessions as part of their usual care, during which their breathing will be assessed using the BPAT at different time points, including before and after treatment. Healthy participants will attend a single assessment visit, and asthma participants' data will be collected from routine clinical care.\n\nThe study will also explore whether BPAT scores change following treatment and whether these changes reflect improvements reported by patients and clinicians.\n\nIn addition, a small number of patients and physiotherapists will be invited to take part in interviews to share their experiences of the assessment process and treatment. This will help understand whether the BPAT is acceptable and useful in clinical practice.\n\nOverall, this study aims to improve how breathing pattern disorder is assessed and monitored, which may help guide better treatment for patients in the future.",[26,27],"Breathing Pattern Disorder","Breathlessness",[27,26,29,30],"Physiotherapy","Assessment","RECRUITING","2026-04-28",{"date":34,"type":35},"2026-05-05","ACTUAL",{"date":37,"type":35},"2024-12-10",{"date":39,"type":22},"2026-05-01",{"name":41,"class":42},"Royal Brompton & Harefield NHS Foundation Trust","OTHER",1,{"id":45,"slug":46,"hasResults":11,"nctId":47,"briefTitle":48,"officialTitle":48,"acronym":4,"eligibilityCriteria":49,"healthyVolunteers":11,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":50,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":51,"conditions":52,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":54,"lastUpdatePostDateStruct":55,"startDateStruct":57,"completionDateStruct":58,"leadSponsor":60,"locationsCount":43},"100631591","diagnostic-accuracy-of-sleepimage-technology-for-detecting-respiratory-failure-in-patients-with-amyotrophic-lateral-sclerosis-100631591","NCT07502677","Diagnostic Accuracy of SleepImage Technology for Detecting Respiratory Failure in Patients With Amyotrophic Lateral Sclerosis","Inclusion Criteria:\n\n* Patients aged 18 and over with a Neurologist confirmed diagnosis of ALS\n\nExclusion Criteria:\n\n* Patients with known respiratory disease\n* Unstable cardiac disease, stable hypertension or ischaemic heart disease\n* Current NIV use\n* Inability to give consent (expected \\~15% due to frontotemporal dementia)",{"count":5,"type":22},"The specific aim of this study is to try to discover the diagnostic accuracy of SleepImage technology for detecting respiratory failure in patients with MND. Importantly, this research project is not about NIV, it is about what method can most efficiently decide when to start NIV.\n\nTo do this we'd like to collect data about you and your breathing from the SleepImage device when you come in for your routine overnight sleep study. We will compare this against the data that we would collect anyway.",[53],"Amyotrophic Lateral Sclerosis","2026-03-24",{"date":56,"type":35},"2026-03-31",{"date":54,"type":35},{"date":59,"type":22},"2027-03-24",{"name":41,"class":42},{"id":62,"slug":63,"hasResults":11,"nctId":64,"briefTitle":65,"officialTitle":65,"acronym":66,"eligibilityCriteria":67,"healthyVolunteers":11,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":68,"targetDuration":4,"studyType":70,"phases":71,"briefSummary":73,"conditions":74,"keywords":76,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":78,"lastUpdatePostDateStruct":79,"startDateStruct":81,"completionDateStruct":83,"leadSponsor":85,"locationsCount":43},"100631297","corticosteroid-tapering-in-sarcoidosis-100631297","NCT07498842","Corticosteroid Tapering in Sarcoidosis","SARC-Taper","Inclusion Criteria:\n\n* Confirmed sarcoidosis by: (a) Histological diagnosis and\u002For (b) Multidisciplinary Team (MDT) diagnosis\n* Prednisolone 5-10mg\u002Fday for \\> 6 months\n* Clinically stable disease for \\> 6 months (no flares or dose escalation)\n* On or off second-line agent\n* \\> 18 years old\n* Written informed consent provided\n\nExclusion Criteria:\n\n* Cardiac or neurosarcoidosis\n* Advanced pulmonary sarcoidosis defined as either: (a) composite physiological index (CPI) \\> 40 (b) pulmonary hypertension\n* Active sarcoidosis flare or dose escalation in the past 6 months\n* Known adrenal insufficiency\n* Pregnancy or breastfeeding\n* Previous or current infliximab use",{"count":69,"type":22},100,"INTERVENTIONAL",[72],"NA","Sarcoidosis is an inflammatory condition affecting many different parts of the body but most commonly the lungs. It is not known what causes sarcoidosis. In some patients no treatment is needed but in other patients long term treatment may be required.\n\nOne of the main medications used to manage this condition is corticosteroids. This medication has been shown to be very effective at reducing inflammation in this condition and many patients often remain on it for months to years.\n\nUnfortunately, there are many negative long-term side effects of corticosteroid use. This includes an increased risk of developing diabetes, reduced bone density, weight gain, high blood pressure and low muscle mass. Currently there are no guidelines for how steroids should be weaned in patients who have stable sarcoidosis.\n\nThe investigators aim to undertake a study at the Royal Brompton Hospital which will be assessing two different steroid tapering regimens which will be allocated to participants in a randomised manner. This will be the first study to directly evaluate different steroid weaning regimens in sarcoidosis patients.\n\nThe main aim of this study is to determine how many participants can reduce their prednisolone dose to less than 50% from their baseline dose. Additionally, the investigators will be recording how many participants require an increase in dose or an additional medication whilst on the prednisolone weaning regimen. The investigators will also see the tolerability of steroid withdrawal and assess for any symptoms of steroid withdrawal. In a small subset of participants the investigators will assess for any changes in body composition and muscle strength using bioelectrical impedance analysis and isometric muscle testing.",[75],"Sarcoidosis",[77],"corticosteroid tapering","2026-03-23",{"date":80,"type":35},"2026-03-27",{"date":82,"type":35},"2026-03-19",{"date":84,"type":22},"2027-10-18",{"name":41,"class":42},{"id":87,"slug":88,"hasResults":11,"nctId":89,"briefTitle":90,"officialTitle":91,"acronym":92,"eligibilityCriteria":93,"healthyVolunteers":17,"sex":18,"minAge":94,"maxAge":4,"enrollmentInfo":95,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":97,"conditions":98,"keywords":101,"overallStatus":109,"whyStopped":4,"lastUpdateSubmitDate":110,"lastUpdatePostDateStruct":111,"startDateStruct":113,"completionDateStruct":115,"leadSponsor":117,"locationsCount":43},"100623884","a-prospective-study-of-advanced-diagnostics-in-people-with-an-unclear-diagnosis-of-cystic-fibrosis-100623884","NCT07402434","A Prospective Study of Advanced Diagnostics in People With an Unclear Diagnosis of Cystic Fibrosis","Advanced Diagnostic Validation and Novel Clinical Evaluation Across the CFTR Spectrum (ADVANCE-CFTR): a Prospective Study of CFTR Functional Assays, Including Rectal Organoids, to Improve the Accuracy of Diagnosing Cystic Fibrosis.","ADVANCE-CFTR","Inclusion Criteria:\n\nGroup A: Difficult Cystic Fibrosis Diagnosis Cohort\n\nInclusion criteria:\n\n1. Patients with difficult-to-diagnose CF\\*\n2. Adults (≥16y)\n3. Willing to undergo rectal biopsy\n4. Able to comply with the study\n\n   * Definition: Non-diagnostic first line CFTR testing (individuals who do not fulfil CF diagnostic criteria \\[2 CF-causing CFTR variants and\u002For sweat chloride concentration ≥60 mmol\u002FL\\]). Of note, there are some individuals with \\\u003C2 CF-causing CFTR variants after extended CFTR genetic analysis but with a SCC \\>60mmol\u002FL. Expansion of the patient pool to include these is permissible.\n\nGroup B: Cystic Fibrosis Patient Cohort\n\nInclusion criteria:\n\n1. Patients with confirmed Cystic Fibrosis\n2. Adults (≥16y)\n3. Willing to undergo rectal biopsy for this study\n4. Able to comply with the study\n\nGroup C: Non-Cystic Fibrosis Patient Cohort\n\nInclusion criteria:\n\n1. Patients without Cystic Fibrosis or CFTR-related disorder\n2. Adults (≥16y)\n3. Willing to undergo rectal biopsy for this study (if undergoing a lower GI endoscopy for other purposes)\n4. Able to comply with the study\n\nExclusion Criteria:\n\nGroup A: Difficult Cystic Fibrosis Diagnosis Cohort\n\nExclusion criteria:\n\n1. Contra-indication to rectal biopsy (e.g. significant bleeding diathesis)\n2. History of lung transplantation\n3. Receiving CFTR modulator treatment\n4. Current participation (or participation within one month of enrolment) in a clinical trial of an investigational medicinal product which affects CFTR function (e.g. CFTR modulators, genetic therapies)\n5. Female who is pregnant or breastfeeding\n6. Unable to provide informed consent\n\nGroup B: Cystic Fibrosis Patient Cohort\n\nExclusion criteria:\n\n1. Contra-indication to rectal biopsy (e.g. significant bleeding diathesis)\n2. Current participation (or participation within one month of enrolment) in a clinical trial of an investigational medicinal product which affects CFTR function (e.g. CFTR modulators, genetic therapies)\n3. Female who is pregnant or breastfeeding\n4. Unable to provide informed consent\n5. Exclude all subjects where diagnosis of CF is in doubt\n\nGroup C: Non-Cystic Fibrosis Patient Cohort\n\nExclusion criteria:\n\n1. Contra-indication to rectal biopsy (e.g. significant bleeding diathesis)\n2. Female who is pregnant or breastfeeding\n3. Unable to provide informed consent","16 Years",{"count":96,"type":22},80,"Sometimes it is very difficult to tell if someone has cystic fibrosis (CF), especially when they have rare CF genes. Without this certainty, they are unlikely to get the correct treatment so their health may be affected. More accurate ways to test for CF are therefore needed in this situation. The aim of this study is to develop a more accurate test using what are called \"organoids\" or \"mini organs.\" Organoids are grown in the laboratory from a small piece of gut tissue. As they have the person's exact genes, they can show if the CF gene (\"CFTR\") is working correctly or not and thus if the person has CF. The investigators will compare the organoid response with the current more established tests, such as the sweat test and CF genetics, and other recognised specialist tests called nasal potential difference (NPD) and intestinal current measurement (ICM). The gut tissue is usually taken by a quick, relatively painless, outpatient procedure (rectal biopsy). The additional benefit of organoids is that they can also help us to work out the best treatment for that individual by testing how well the gut tissue responds to different drugs in the laboratory. The investigators wish to carry out this research to prove that gut organoids are a better way to test for CF in this situation. The goal will be to diagnose people faster and for them to get better treatment quicker, both key for leading a longer and healthier life.",[99,100],"Cystic Fibrosis (CF)","CFTR-related Disorders",[102,103,104,99,105,106,107,108],"CFTR-related disorders","Advanced Diagnostics","Personalised medicine","Nasal potential difference (NPD)","Intestinal current measurements (ICM)","Organoids","Sweat chloride concentration (SCC)","NOT_YET_RECRUITING","2026-02-12",{"date":112,"type":35},"2026-02-17",{"date":114,"type":22},"2026-02-02",{"date":116,"type":22},"2028-09-01",{"name":41,"class":42},{"id":119,"slug":120,"hasResults":11,"nctId":121,"briefTitle":122,"officialTitle":123,"acronym":4,"eligibilityCriteria":124,"healthyVolunteers":11,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":125,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":127,"conditions":128,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":130,"lastUpdatePostDateStruct":131,"startDateStruct":133,"completionDateStruct":135,"leadSponsor":137,"locationsCount":43},"100612687","identifying-the-optimal-imt-dose-in-icu-100612687","NCT07256821","Identifying the Optimal IMT Dose in ICU","A Prospective, Mixed Methods, Observational Study to Define a Diaphragm-focussed and Patient-acceptable Inspiratory Muscle Training (IMT) Load in Difficult to Wean, Mechanically Ventilated Patients","Inclusion Criteria:\n\n* Mechanically ventilated patients with a tracheostomy\n* Aged ≥ 18 years\n* Co-operative and able to participate in IMT.\n* Informed consent or surrogate approval\n\nExclusion Criteria:\n\n* Facial or skull fracture, or a bleeding disorder which would prohibit oesophageal catheter placement.\n* Undrained pneumothorax\u002Fpneumomediastinum.\n* Delirium or deep sedation that impedes the patient's ability to participate in study procedures\n* Pregnancy\n* Unlikely to survive, or consultant assessment that the patient is not appropriate.\n* Wounds that prohibit EMG electrode placement.",{"count":126,"type":22},40,"200,000 adults are admitted to intensive care in the UK each year. Many of these patients need help with their breathing and are put on a machine called a ventilator.\n\nResearch shows that many patients using a ventilator quickly develop weakness in their main breathing muscle, called the diaphragm. This weakness can cause a longer time on the ventilator, a longer hospital stay, and higher chances of health problems or death.\n\nInspiratory muscle training is a breathing exercise where the patient breathes against resistance through a small device (like breathing through a straw). It aims to improve the strength of the diaphragm and reduce how long patients are on the ventilator.\n\nWhy is this research needed?\n\nResearch shows that current breathing exercise programmes do not help patients come off the ventilator or go home quicker. This may be because these breathing exercises strengthen the wrong muscles (those in the chest and neck, that are not efficient). These exercises can also be distressing for patients.\n\nWhat will be done in this research? This research aims to develop a breathing exercise programme that focusses on strengthening the diaphragm. We will also make sure patients do not find the breathing exercise too distressing.\n\nThis research will measure how the breathing muscles respond to four different levels of breathing exercise and ask patients to feedback on each level.\n\n1. At each breathing exercise level, the effort of the breathing muscles will be measured using a small tube inserted into the nostril and small sticky patches on the chest and neck. We aim to find the level where the diaphragm is being pushed to work hard but other muscles in the chest and neck are not.\n2. After each breathing exercise level patients will be asked how they found it - for example, easy, pleasant, scary.\n\nThis procedure will be repeated 1-3 times over seven days with at least 24 hours between each measurement",[129],"Difficult to Wean, Mechanically Ventilated Patients With a Tracheostomy","2026-01-08",{"date":132,"type":35},"2026-01-12",{"date":134,"type":35},"2025-11-23",{"date":136,"type":22},"2027-01",{"name":41,"class":42},{"id":139,"slug":140,"hasResults":11,"nctId":141,"briefTitle":142,"officialTitle":142,"acronym":143,"eligibilityCriteria":144,"healthyVolunteers":11,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":145,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":147,"conditions":148,"keywords":151,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":155,"lastUpdatePostDateStruct":156,"startDateStruct":157,"completionDateStruct":159,"leadSponsor":161,"locationsCount":43},"100618476","a-pilot-study-to-assess-body-mass-composition-measurement-using-bia-and-muscle-ultrasound-in-ipf-and-ppf-patients-on-anti-fibrotic-medications-100618476","NCT07332117","A Pilot Study to Assess Body Mass Composition Measurement Using BIA and Muscle Ultrasound in IPF and PPF Patients on Anti-fibrotic Medications","AF-BMC","Inclusion Criteria:\n\n* A diagnosis of Idiopathic pulmonary fibrosis or progressive pulmonary fibrosis\n* Newly commencing anti-fibrotic medication (either nintedanib or pirfenidone)\n* Subject aged \\> 18 years\n* Able to willingly give consent\n\nExclusion Criteria:\n\n* Co-morbidities currently requiring enteral feeding\n* Weight loss \\> 10% in preceding 3-6 months\n* Significant musculoskeletal issues that may impact muscle mass\n* End of life care (expected \\\u003C 6 weeks left to live)\n* Previous anti-fibrotic use\n* Currently on \\> Prednisolone 10mg daily\n* Presence of implantable cardioverter defibrillator (ICD) or permanent pacemaker (PPM)\n* Heart failure\n* Pregnancy",{"count":146,"type":22},30,"To assess the impact on body mass composition from anti-fibrotic medications used in fibrotic lung disease by using BIA and muscle ultrasound",[149,150],"Idiopathic Pulmonary Fibrosis (IPF)","Progressive Pulmonary Fibrosis",[152,153,154],"bioimpedance analysis","muscle ultrasound","body composition","2025-12-31",{"date":132,"type":35},{"date":158,"type":35},"2025-09-09",{"date":160,"type":22},"2026-04",{"name":41,"class":42},{"id":163,"slug":164,"hasResults":11,"nctId":165,"briefTitle":166,"officialTitle":167,"acronym":168,"eligibilityCriteria":169,"healthyVolunteers":11,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":170,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":171,"conditions":172,"keywords":174,"overallStatus":109,"whyStopped":4,"lastUpdateSubmitDate":180,"lastUpdatePostDateStruct":181,"startDateStruct":183,"completionDateStruct":185,"leadSponsor":187,"locationsCount":43},"100615358","precision-detection-and-prediction-of-atrial-arrhythmias-using-artificial-intelligence-and-consumer-wearable-devices-100615358","NCT07291570","Precision Detection and Prediction of Atrial Arrhythmias Using Artificial Intelligence and Consumer Wearable Devices","Precision Detection and Prediction of Atrial Arrhythmias Using Artificial Intelligence and Consumer Wearable Devices (REMOTE-AF2)","REMOTE-AF2","Inclusion Criteria:\n\n1. Adults aged 18 and above with a confirmed diagnosis of paroxysmal AF or those who have undergone treatment for paroxysmal, or persistent AF and had sinus rhythm restored.\n2. Capability to provide informed consent, coupled with self-reported sufficiency of digital literacy.\n3. Regular access to a Wi-Fi connection (at least weekly).\n4. Own a smartphone (released after 2017).\n\nExclusion Criteria:\n\n1. Individuals with permanent or persistent AF that remains uncontrolled despite receiving treatment.\n2. Conditions or disabilities that preclude adherence to study instructions or proper use of the devices.\n3. A known severe allergy to any of the materials in the wearable or ECG device poses a risk to participant safety.",{"count":126,"type":22},"Atrial fibrillation (AF) is the most prevalent cardiac arrhythmia affecting over one million people in the UK. It is associated with increased cardiovascular morbidity and mortality and costs the NHS between £1.4 billion and 2.5 billion annually. Current methods to detect AF include opportunistic pulse palpation, single time point 12-lead electrocardiograms (ECGs), ambulatory Holter monitoring, and implantable loop recorders (ILRs). The more widely used intermittent monitoring methods, such as ECGs and Holter monitoring, are limited in terms of duration and have lower detection yields of atrial arrhythmias. At the other end of the spectrum, the ILR can give continuous and accurate arrhythmia detection but is invasive and requires specialist expertise to implant, monitor, and analyse.\n\nIn recent years, the use of wearable mobile health (mHealth) devices has emerged as a direct-to-consumer option for monitoring parameters such as heart rate and activity levels. From a clinical perspective they potentially offer a less invasive and cost-effective investigative approach, with remote monitoring solutions to possibly predict and detect AF. This technology has significant potential in terms of passive, non-invasive and continuous monitoring to aid the early diagnosis and management of AF.\n\nThe original REMOTE-AF study (NCT05037136) developed novel methodology to detect AF using PPG-dervived data from a wearable. This study will further enhance this foundational work by recruiting patients to develop a AI-enabled, multi-parametric algorithm using PPG-derived data to detect AF.",[173],"Atrial Fibrillation (AF)",[175,176,177,178,179],"atrial fibrillation","remote monitoring","artificial intelligence","wearables","photophlethysmography (PPG)","2025-12-05",{"date":182,"type":35},"2025-12-18",{"date":184,"type":22},"2025-12",{"date":186,"type":22},"2026-08",{"name":41,"class":42},{"id":189,"slug":190,"hasResults":11,"nctId":191,"briefTitle":192,"officialTitle":193,"acronym":194,"eligibilityCriteria":195,"healthyVolunteers":11,"sex":18,"minAge":4,"maxAge":4,"enrollmentInfo":196,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":198,"conditions":199,"keywords":203,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":206,"lastUpdatePostDateStruct":207,"startDateStruct":209,"completionDateStruct":211,"leadSponsor":213,"locationsCount":43},"100577354","a-study-of-females-with-cf-throughout-pregnancy-and-post-partum-and-follow-up-of-their-offspring-100577354","NCT06797206","A Study of Females With CF Throughout Pregnancy and Post-partum, and Follow up of Their Offspring","An Observational Study to Evaluate the Impact of Pregnancy and Parenthood in Females With Cystic Fibrosis and Their Offspring in the CFTR Modulator Era.","MATRIARCH_CF","Inclusion Criteria:\n\n'Mama' sub-study:\n\n* Written informed consent obtained from participant.\n* Under the care of Royal Brompton Hospital CF Reproductive and Maternal Health Service\n* Age 16 years or above at time of recruitment\n* Confirmed diagnosis of CF\n* Planning a pregnancy or pregnant at time of recruitment.\n* Ability to adhere to the required visits and investigations.\n\n'Mini' sub-study:\n\n* Written informed consent obtained from participant's legal guardian.\n* Infants who have one biological parent with a confirmed diagnosis of CF under care of Royal Brompton Hospital Adult CF Service\n* Less than 12 months of age at first visit.\n* Ability to adhere to the required visits and investigations.\n\n'Midi' sub-study:\n\n* Written informed consent obtained from participant's legal guardian.\n* Children who have one biological parent with a confirmed diagnosis of CF who is under the care of Royal Brompton Hospital Adult CF Service.\n* Age three to six years at time of visit\n* Ability to adhere to the required visits and investigations.\n\nExclusion Criteria:\n\n'Mama' sub-study:\n\n* Any significant health condition which would cause inability to comply with protocol based on investigator discretion.\n* History of lung transplantation\n\n'Mini' sub-study:\n\n* Legal guardians' inability to provide consent to participate in the study.\n* Mother of infant has significant comorbidities unrelated to CF which could affect infant outcomes based on investigator discretion.\n\n'Midi' sub-study:\n\n* Legal guardians' inability to provide consent to participate in the study.\n* A significant health condition which is known to affect lung function or imaging based on investigator discretion",{"count":197,"type":22},60,"In this study, investigators aim to study in detail the physical (including nutritional and pulmonary) and mental health of females with cystic fibrosis (CF) planning a pregnancy, during pregnancy, and in the early parenthood period.\n\nAdditionally the health of offspring in infancy and early life will be studied to understand if further screening investigations or clinical care models should be part of clinical guidelines",[99,200,201,202],"Pregnancy","Infant, Newborn","Exposure During Pregnancy",[204,200,205],"Pregnancy\u002Fobstetric health in women with cystic fibrosis","CFTR modulators","2025-09-26",{"date":208,"type":35},"2025-10-01",{"date":210,"type":35},"2025-06-12",{"date":212,"type":22},"2028-05",{"name":41,"class":42},{"id":215,"slug":216,"hasResults":11,"nctId":217,"briefTitle":218,"officialTitle":219,"acronym":4,"eligibilityCriteria":220,"healthyVolunteers":11,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":221,"targetDuration":223,"studyType":23,"phases":4,"briefSummary":224,"conditions":225,"keywords":229,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":231,"lastUpdatePostDateStruct":232,"startDateStruct":234,"completionDateStruct":236,"leadSponsor":238,"locationsCount":239},"100581759","aveir-leadless-pacemaker-lp-united-kingdom-uk-registry-100581759","NCT06854484","AVEIR™ Leadless Pacemaker (LP) United Kingdom (UK) Registry","AVEIR™ Leadless Pacemaker United Kingdom Registry","Inclusion Criteria:\n\n1. Patient is intended to receive or was treated with a (AVEIR™) Leadless Transcatheter Pacing\n2. Subject is willing to comply with clinical investigation procedures and agrees to return for all required follow-up visits, tests, and exams; and\n3. Subject has been informed of the nature of the study, agrees to its provisions, and has provided a signed written informed consent, approved by the Regional Ethics Committee (REC).\n\nExclusion Criteria:\n\n1. Subject is not suitable for implantation of the leadless device according to the expert opinion of their cardiologist.\n2. Subject is not willing to comply with clinical investigation procedures and does not agree to return for all required follow-up visits, tests, and exams\n3. Subject has been informed of the nature of the study, but does not agree to its provisions, and has not provided a signed written informed consent, approved by the REC",{"count":222,"type":22},300,"5 Years","This observational study will follow patients requiring implantation of leadless pacemaker for 5 years after implantation. The main goal is to evaluate the long term safety and efficacy of AVEIR™ leadless pacemaker device in the usual clinical settings within the UK National Health Service. In addition, the study will collect data to understand patient characteristics receiving this type of pacemaker.",[226,227,228],"Bradycardia","Atrio-Ventricular Block","Syncope",[230],"AVEIR leadless pacemaker","2025-07-24",{"date":233,"type":35},"2025-07-29",{"date":235,"type":35},"2025-04-15",{"date":237,"type":22},"2032-09",{"name":41,"class":42},2,{"id":241,"slug":242,"hasResults":11,"nctId":243,"briefTitle":244,"officialTitle":245,"acronym":246,"eligibilityCriteria":247,"healthyVolunteers":17,"sex":18,"minAge":248,"maxAge":94,"enrollmentInfo":249,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":251,"conditions":252,"keywords":256,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":262,"lastUpdatePostDateStruct":263,"startDateStruct":265,"completionDateStruct":267,"leadSponsor":268,"locationsCount":239},"100566907","evaluation-of-exercise-testing-and-physical-activity-in-children-and-adolescents-living-with-inherited-arrhythmias-100566907","NCT06661278","Evaluation of Exercise Testing and Physical Activity in Children and Adolescents Living With Inherited Arrhythmias","Evaluation of Free-living Physical Activity and the Assessment Tools Used to Support Pharmacological Therapy Titration and Exercise Prescription in Children and Adolescents Diagnosed With Inherited Arrhythmias","ACTIVELY","Inclusion Criteria:\n\nAffected cohort\n\n* Male and female children\n* Aged 6-16 years\n* Diagnosed with long QT syndrome or catecholaminergic polymorphic ventricular tachycardia\n* Treated with beta-blocker and\u002For sodium channel blockade\n* Able to complete a treadmill ETT\n\nHealthy cohort\n\n* Male and female children\n* Aged 6-16 years\n* Siblings of affected children (gene negative)\n* Undergoing IAS screening\n* Able to complete a treadmill ETT\n\nExclusion Criteria:\n\n* Children aged less than 6 years\n* Adults, 17 years of age and above\n* Unable to run on an exercise treadmill due to physical limitations.\n* Individuals unable to speak or understand English, due to no translation service available.\n* Pregnancy","6 Years",{"count":250,"type":22},110,"The goal of this observational study is to evaluate exercise testing and daily physical activity in children and adolescents who are diagnosed with an inherited arrhythmia.\n\nThe main question it aims to answer is: Does maximum heart rate during controlled exercise tolerance testing accurately reflect maximum heart rate and peak exercise levels during free living daily physical activity in children and adolescents diagnosed with an inherited arrhythmia?\n\nParticipants will:\n\n* Complete routine exercise tolerance testing\n* Record daily physical activity and exercise over two weeks, while wearing an activity and heart rate monitor and digit diary.\n* Complete a physical activity questionnaire at the end of two weeks.",[253,254,255],"Long QT Syndrome","Catecholaminergic Polymorphic Ventricular Tachycardia Type 1","Catecholaminergic Polymorphic Ventricular Tachycardia Type 2",[257,258,259,260,261],"Children","Adolescents","Exercise","Physical activity","Exercise tolerance testing","2025-05-30",{"date":264,"type":35},"2025-05-31",{"date":266,"type":35},"2025-03-18",{"date":155,"type":22},{"name":41,"class":42},{"id":270,"slug":271,"hasResults":11,"nctId":272,"briefTitle":273,"officialTitle":273,"acronym":4,"eligibilityCriteria":274,"healthyVolunteers":11,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":275,"targetDuration":276,"studyType":23,"phases":4,"briefSummary":277,"conditions":278,"keywords":281,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":287,"lastUpdatePostDateStruct":288,"startDateStruct":290,"completionDateStruct":292,"leadSponsor":294,"locationsCount":43},"100546660","a-prospective-observational-single-centre-study-to-assess-the-feasibility-of-the-data-harvested-by-the-acorai-intracardiac-pressure-monitoring-icpm-system-in-predicting-prognosis-in-patients-discharged-from-hospital-after-treatment-for-acute-decompensated-heart-failure-100546660","NCT06397833","A Prospective, Observational, Single Centre Study to Assess the Feasibility of the Data Harvested by the Acorai Intracardiac Pressure Monitoring (ICPM) System in Predicting Prognosis in Patients Discharged From Hospital After Treatment for Acute Decompensated Heart Failure","Inclusion Criteria: Subjects must meet all the following criteria to be eligible for participation in the clinical investigation\n\n1. Subjects medically fit for discharge following an admission to Hospital with decompensated heart failure requiring intravenous diuretic therapy\n2. Subject is willing and physically able to comply with the specified evaluations as per clinical investigation plan, as assessed by the investigator.\n3. Subject is able to provide written consent to participate in the study\n\nExclusion Criteria:\n\n1. Pregnancy\n2. Discretionary exclusion when, in the opinion of the investigator, the inclusion of a potential subject is not in their best interest or not in the interest of compliant performance of the clinical trial",{"count":21,"type":22},"1 Year","Acorai is developing the Acorai Heart Monitor, a handheld electronic device for monitoring pressures inside the heart in a non-invasive manner, by placing the device on the chest of a patient. Currently these intracardiac pressures are measured in an invasive way, during a right heart catheterisation procedure. This procedure carries risks to the patient. There is a clinical need for a non -invasive, easy to use, tool to monitor patients that suffer from heart failure. The study aim is to use the Acorai device to collect the intracardiac pressure measurements from patients admitted to hospital with heart failure and who are awaiting discharge home. Using the data, we will assess the feasibility of the Acorai derived cardiac output measurements, and assess what data best predicts survival, death, or major adverse cardiac events (MACE)",[279,280],"Heart Failure","Decompensated Heart Failure",[282,283,284,177,285,286],"heart failure","decompensated heart failure","acorai","machine learning generisation","machine learning generization","2025-04-04",{"date":289,"type":35},"2025-04-08",{"date":291,"type":35},"2024-04-29",{"date":293,"type":22},"2027-02-01",{"name":41,"class":42},{"id":296,"slug":297,"hasResults":11,"nctId":298,"briefTitle":299,"officialTitle":299,"acronym":300,"eligibilityCriteria":301,"healthyVolunteers":11,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":302,"targetDuration":4,"studyType":70,"phases":303,"briefSummary":304,"conditions":305,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":308,"lastUpdatePostDateStruct":309,"startDateStruct":311,"completionDateStruct":313,"leadSponsor":315,"locationsCount":43},"100525996","trans-coronary-cooling-and-dilution-for-cardioprotection-during-revascularisation-for-st-elevation-myocardial-infarction-100525996","NCT06128993","Trans-coronary Cooling and Dilution for Cardioprotection During Revascularisation for ST-elevation Myocardial Infarction","STEMI-Cool","Inclusion Criteria:\n\n* Clinical ST-elevation myocardial infarction or equivalent (e.g. new onset LBBB)\n* \\\u003C12 Hrs after symptom onset\n* Thrombolysis in myocardial infarction (TIMI) 0-1 coronary flow in a target vessel\n\nExclusion Criteria:\n\n* History of severe asthma\n* Pregnancy\n* Severe concomitant disease or conditions with a life expectancy of less than one year.",{"count":197,"type":22},[72],"A heart attack (myocardial infarction) occurs when an artery supplying blood to the heart is suddenly blocked resulting in damage to the heart muscle.\n\nPatients presenting to hospital with a heart attack undergo an immediate angiogram (x-ray of the arteries in the heart) and are usually treated immediately with a balloon and stent to open their blocked artery. This procedure is called \"primary percutaneous coronary intervention\" (or primary PCI for short).\n\nAn angiogram is a routine procedure that involves insertion of fine plastic tube (catheter) into either the groin or wrist under local anaesthetic. The tube is passed into the artery in the heart and X-ray pictures are taken to find out if the arteries are blocked. Blocked arteries can usually be opened by passing a small balloon into the artery, via the fine plastic tube followed by placement of a stent (a fine metal coil) into the artery to prevent it from blocking again.\n\nAlthough this treatment is very successful, it can result in damage to the heart muscle when the artery is opened. Cooling the entire body has been shown to reduce heart muscle damage during heart attacks in some patients but not in others; however, it is uncomfortable due to the shivering, expensive and can result in delays in opening the blocked artery.\n\nThe investigators are conducting a series of research studies to find out if cooling the heart muscle directly through the catheter being used for the normal primary angioplasty treatment using room temperature may be effective in preserving heart muscle, without the shortcomings of entire body cooling.\n\nThe investigators have already published an initial series of ten cases in which this treatment appeared to be feasible without causing significant clinical problems.\n\nThe present study is a pilot study designed to assess the rate of patient recruitment and feasibility of this new treatment while exploring some detailed outcomes measuring the restoration of blood flow within the coronary artery at the end of the procedure.\n\nUltimately if the present pilot study is successful, the investigators plan to go on to undertake a much larger randomised outcome study to determine definitively whether this treatment can help reduce heart attack size.",[306,307],"Myocardial Infarction","Reperfusion Injury, Myocardial","2025-01-29",{"date":310,"type":35},"2025-01-31",{"date":312,"type":35},"2023-11-01",{"date":314,"type":22},"2026-01",{"name":41,"class":42},{"id":317,"slug":318,"hasResults":11,"nctId":319,"briefTitle":320,"officialTitle":321,"acronym":4,"eligibilityCriteria":322,"healthyVolunteers":11,"sex":18,"minAge":94,"maxAge":323,"enrollmentInfo":324,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":326,"conditions":327,"keywords":328,"overallStatus":109,"whyStopped":4,"lastUpdateSubmitDate":332,"lastUpdatePostDateStruct":333,"startDateStruct":335,"completionDateStruct":337,"leadSponsor":339,"locationsCount":43},"100556724","coronary-artery-disease-in-hearts-donated-for-transplantation-100556724","NCT06528834","Coronary Artery Disease in Hearts Donated for Transplantation","Coronary Angiographic Assessment of Hearts Donated for Transplantation Declined on the Grounds of Visible\u002FPalpable Coronary Artery Disease at the Time of Retrieval","Inclusion Criteria:\n\nHearts donated for transplantation which are retrieved by the Harefield Hospital retrieval team which are deemed untransplantable on the grounds of visible or palpable coronary artery disease of the epicardial arteries at the time of retrieval.\n\n\\-\n\nExclusion Criteria:\n\nAbsence of family consent to retrieve untransplantable heart for research purposes\n\nLogistic challenges","80 Years",{"count":325,"type":22},10,"In spite of recent initiatives, in particular, the introduction into clinical practice of donation after circulatory death (DCD), there is a persistent mismatch between the demand for donor hearts for transplantation and their supply \\[1\\]. This mismatch is accentuated by the relatively low rate of utilisation of hearts donated for transplantation, i.e. the proportion of organs transplanted divided by the number of donations. In the UK between 2016 and 2018 this ranged from 25.7 to 30.8% \\[2\\]. For the year 2022\u002F23, a total of 207 heart transplants (DBD and DCD) were performed out of 1429 donations giving a utilisation rate of 14.5% \\[3\\].\n\nThe rigorous assessment of donor heart quality prior to, and during donor organ retrieval, which is a crucial determinant of recipient outcome, accounts for the low utilisation rate. In both the donation after brain(stem) death (DBD) and DCD settings, pre-retrieval echocardiography is the principal method of anatomical and functional assessment. In the DCD setting, where normothermic organ perfusion (either in situ or ex situ) is mandatory to restore myocardial function, additional functional and biochemical assessments are available.\n\nIn addition to recipient risk factors, donor age and comorbidity burden continue to limit the applicability and effectiveness of heart transplantation. Older donors are both associated with an increased comorbidity burden and prevalence of coronary artery disease (CAD). Donor-transmitted CAD is of particular concern due to the significant association with early graft dysfunction when multi-vessel disease is present \\[4,5\\]. Guidelines recommend that donor hearts with obstructive CAD in any major coronary artery be declined for transplantation \\[4\\]. However, there is evidence that single vessel CAD neither alters short- nor long term recipient prognosis \\[6\\]. The short and long term risks to the recipient of donor heart CAD needs to be carefully evaluated in relation to the risk of a transplant candidate remaining on the waiting list \\[7,8\\].\n\nNone of the methods currently available in the UK for the assessment of potential heart donors allows adequate characterisation of coronary artery disease (CAD). Instead, retrieval surgeons place a heavy reliance on an indirect assessment of CAD, i.e. direct visualisation and palpation of the large epicardial coronary arteries with the aim of identifying occlusive lesions. The discovery of such lesions is the justification for declining a donor organ otherwise deemed to be suitable for transplantation.\n\nIn other countries, access to coronary artery imaging prior to heart donation is an established option, where indicated. Indeed, the Association of Organ Procurement Organizations Consensus Statement, supported by the Society of Critical Care Medicine and the American College of Chest Physicians recommends coronary angiography in all older donors (\\>40 years) and in younger patients with risk factors for CAD.\n\nIn the proposed study we seek to perform coronary angiography at Harefield Hospital on donated hearts where our retrieval team has declined the organ solely on the grounds of visible\u002Fpalpable CAD. In so doing we aim to better understand the diagnostic utility of the assessment method. An internal audit of heart retrieval has revealed that of the donated hearts offered to Harefield since 2020 between 8 to 13 are declined per annum on the grounds of visible\u002Fpalpable coronary artery disease, i.e. approx. 10 per annum. Assuming a study enrolment rate of 1:3 of donated hearts with CAD identified at the time of retrieval, we therefore anticipate that this study will take 36 months to complete. This investigation forms part of a broader research\u002Fservice improvement initiative which aims to not only enhance the assessment of CAD in potential donors but also to better understand the pathogenesis of CAD in heart transplant recipients. The ultimate goals are to reduce the risks associated with transplantation and increasing donor organ availability. We propose to initiate this investigation as a single centre study but would welcome the participation of other UK centres who would like to collaborate.\n\nWe believe this research initiative is well aligned with the strategic objectives of the NHS BT Business Plan 2022-23 \\[9\\].\n\n1. Hsich E. Circ. Heart. Fail. 2016 Apr. 9(4) e002679.\n2. Rushton and Hogg March 2019 NHSBT\u002FCAG, CHARH(19)25.\n3. NHS-BT Annual Activity Report:Section 7, Cardiothoracic activity. 2022-23.\n4. Ivanes F et al. Int J Cardiol. 2019 277;71-8.\n5. Kotloff RM et al. Crit Care med. 2015;43:1291-325.\n6. Dorent et al. Arch. Cardiovasc. Dis. 2018;111:126-39.\n7. Kilic A et al. J Thorac Dis. 2014;6:1097-104.\n8. Estevz-Loureiro R et al. Transplant. Proc. 2010;42:2987-91.\n9. NHS BT Business Plan 2022-23, July 2022.",[279],[329,330,331],"heart transplantation","coronary artery disease","coronary angiography","2024-07-26",{"date":334,"type":35},"2024-07-30",{"date":336,"type":22},"2024-09",{"date":338,"type":22},"2027-09",{"name":41,"class":42},{"id":341,"slug":342,"hasResults":11,"nctId":343,"briefTitle":344,"officialTitle":345,"acronym":4,"eligibilityCriteria":346,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":347,"enrollmentInfo":348,"targetDuration":4,"studyType":70,"phases":350,"briefSummary":351,"conditions":352,"keywords":4,"overallStatus":109,"whyStopped":4,"lastUpdateSubmitDate":354,"lastUpdatePostDateStruct":355,"startDateStruct":357,"completionDateStruct":359,"leadSponsor":361,"locationsCount":4},"100555988","a-pilot-study-evaluating-the-potential-of-18f-fluorodeoxyglucose-pet-ct-imaging-in-diagnosing-cardiac-rejection-100555988","NCT06519240","A Pilot Study Evaluating the Potential of 18F Fluorodeoxyglucose PET-CT Imaging in Diagnosing Cardiac Rejection.","A Prospective Blinded Pilot Study Evaluating the Sensitivity and Specificity of 18F Fluorodeoxyglucose PET CT Imaging (a Non-invasive Imaging Tool) for the Diagnosis of Rejection in Heart Transplant Recipients.","Inclusion Criteria:\n\n* All heart transplant recipients with definite cardiac rejection or definite no rejection with evidence of no significant coronary disease within the last 12 months (e.g with any of the following tests (1)angiogram (2) CTCA (3) MPS (4) CMR (5) other coronary ischaemia test)\n\nExclusion Criteria:\n\n* Unable to have a PET CT scan or comply with the dietary protocol\n* Age less than 18 years old\n* Unable to consent\n* Presence of significant coronary disease or coronary ischaemia\n* Insulin dependent diabetics\n* Pregnant or breast feeding individuals","99 Years",{"count":349,"type":22},20,[72],"This pilot study aims to assess whether 18F-FDG PET CT imaging has the potential in diagnosing cardiac rejection. The investigators aim to recruit 20 heart transplant subjects within two groups of 10 subjects each. One group will have participants with definite rejection and the other group will have participants with definite no rejection. Subjects will be placed into study groups based on their heart muscle biopsy, echocardiogram, clinical symptoms, ECG, and presence or absence of donor specific antibodies. Each group will then undertake a 18F-FDG PET CT scan to identify whether this imaging modality has a role in identifying cardiac rejection. The study subjects and the research team will be blinded to the results of the PET CT until the end of the study.",[353],"Cardiac Transplant Rejection","2024-07-22",{"date":356,"type":35},"2024-07-25",{"date":358,"type":22},"2024-09-30",{"date":360,"type":22},"2026-10-02",{"name":41,"class":42},{"id":363,"slug":364,"hasResults":11,"nctId":365,"briefTitle":366,"officialTitle":366,"acronym":367,"eligibilityCriteria":368,"healthyVolunteers":11,"sex":18,"minAge":4,"maxAge":4,"enrollmentInfo":369,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":371,"conditions":372,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":374,"lastUpdatePostDateStruct":375,"startDateStruct":377,"completionDateStruct":379,"leadSponsor":381,"locationsCount":239},"100379266","the-harefield-acute-myocardial-infarction-cohort-100379266","NCT04218344","The Harefield Acute Myocardial Infarction Cohort","HEART - ACS","Inclusion Criteria:\n\n• All patients presenting to Harefield Hospital through the Primary Percutaneous Coronary Intervention programme, with ST-segment elevation myocardial infarction, non ST-segment elevation myocardial infarction, unstable angina, Tako Tsubo syndrome, spontaneous coronary artery dissection and acute myocarditis, with the intention to assess with coronary angiography.\n\nExclusion Criteria:\n\n* Patients will be able to self-exclude if they do not provide full informed consent\n* Every effort will be made to obtain informed consent from all patients.\n* Patients who do not survive the hospital episode will undergo a Professional or Personal Consultee process of assumed consent.",{"count":370,"type":22},2000,"In this project the investigator's plan to collect blood during a patient's routine angiogram procedure which they will have due to having suffered a heart attack. Data from the patients' routine procedures for this condition, including but not exclusively, ECG, Echocardiogram, MRI scans, will be collected. The aim of the research project is to analyse the blood samples and identify novel biomarkers and clinical parameters associated with acute coronary syndromes. The investigator's will particularly focus on markers of inflammation and micro-organism activity. The investigator's hope that this will help to gain more knowledge about what causes heart disease and how various conditions can be treated more efficiently. The investigator's will follow-up and collect further research data via a questionnaire at the routine 6 weeks and 6 months follow-up appointment after the angiogram procedure. Participants will also be telephoned at one-year post procedure, to update any events and medication status and data will thereafter be collected form data held by the hospital without having to contact the participant. Remaining blood samples will be stored securely for further analysis into blood and other markers.",[373],"Acute Coronary Syndrome","2020-01-13",{"date":376,"type":35},"2020-01-18",{"date":378,"type":35},"2020-01-09",{"date":380,"type":22},"2035-12-31",{"name":41,"class":42},""]